Sign in
CompletedPhase 1

A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels

Key facts

Who runs it
Protalix
Where
New Zealand2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
64 people enrolled
Started
23 Mar 2023
Ended
6 Feb 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • PRX-115
  • Placebo
Record updated
11 February 2025

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Males or females 18 to 65 years of age, inclusive
  • Serum uric acid greater than 6.0 mg/dL (0.35 mmol/L) at the Screening visit
  • Body mass index within the range 18.5 to 40 kg/m\^2, inclusive, at the Screening visit
  • Women of childbearing potential may be included only if they have a negative beta human chorionic gonadotropin (β-hCG) test result at Screening
  • Men and women of childbearing potential and their partners should use double barrier contraception

Who cannot take part

  • Had greater than or equal to 1 gout flare in the last year prior to either Screening or Day -1
  • History of autoimmune disorders, and/or participant is immunocompromised or treated with immunosuppressive medications
  • Concurrent treatment with urate lowering drugs (ULDs)
  • Prior exposure to any experimental or marketed uricase (eg, rasburicase [Elitek, Fasturtec], pegloticase [Krystexxa®], pegadricase [SEL-212])
  • Has any condition known to have arthritis as a clinical manifestation
  • History of significant renal disease, and/or presence of renal stones at either Screening or Day -1
  • Has a history of anaphylaxis, severe allergic reactions, or severe atopy
  • Has evidence of cardiovascular or cerebrovascular disease
  • History of congestive heart failure, New York Heart Association Class III or IV
  • Participants with hypertension who are not on stable medication for at least 6 months
  • Has uncontrolled type 2 diabetes
  • Estimated glomerular filtration rate (eGFR) value less than or equal to 60 mL/min/1.73m\^2
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency or known catalase deficiency
  • Has clinical evidence of subcutaneous tophi at either Screening or Day -1
  • BP outside the range of 90 to 150 mm Hg for systolic or 50 to 95 mm Hg for diastolic

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a Phase 1, double-blind, placebo-controlled, single ascending dose study in participants with elevated uric acid levels. This study will be conducted in approximately 64 adult male and female participants in the dose escalation phase.

The 2 groups in the trial

  • PRX-115Treatment being tested

    Participants will receive a single dose of PRX-115 by IV infusion

  • PlaceboPlacebo, for comparison

    Participants will receive a single dose of placebo by IV infusion

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels.
Record updated
11 February 2025